Incyte Corporation - Common Stock · Transaction May 15, 2025 · Filed May 31, 2025 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · INCY
-1.57% · -$1.84 · Vol 2.2M
Market closed · last close 4:00 PM ET · price as of 17:29:12 ET
Incyte Corp
Biotechnology
$115.30
Follow $INCY
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $INCY by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredFri Oct 2 · last completed session · Markets closed · resumes Mon 9:30 ET · INCY
MethodologyINCY
Incyte Corp
Fri Oct 2 · last completed session · Markets closed · resumes Mon 9:30 ET
Upper range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
70/ 100
Veridion Score
Upper range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Fri Oct 2 · last completed session · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is INCY moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Incyte Corp
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCHListed since
1993
Employees
3K
Country
US
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$116.76
Day high
$117.19
Day low
$114.57
Previous close
$117.14
52W high
$129.93
-11.26% from high
52W low
$83.80
68% of range
Market cap
$23.7B
P/E
14.62×
EPS
$7.85
Beta
-0.36
Shares out
202.7M
Volume
2.2M
1.47× rel vol
Avg volume
1.5M
VWAP
$115.49
Price history computed in-house
1W
-6.93%
1M
-9.92%
3M
-1.33%
1Y
+32.76%
YTD
+16.74%
SMA 50 $123.63 · below
SMA 200 $106.86 · above
52W position 68%
INCY overview
Related filings and maps
Public disclosures
Congress activity in INCY
Official filing ↗
Incyte Corporation · Transaction Mar 6, 2023 · Filed Apr 17, 2023 · $1,001 to $15,000
Incyte Corporation · Transaction Dec 22, 2020 · Filed Jan 11, 2021 · $1,001 to $15,000
Incyte Corporation · Transaction Sep 16, 2020 · Filed Oct 14, 2020 · $1,001 to $15,000
Incyte Corporation · Transaction Nov 12, 2018 · Filed Dec 8, 2018 · $1,001 to $15,000
Federal contracts
INCY contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for INCY in this window.
Lobbying spend
INCY lobbying filings, year to date.
Registered lobbying filings matched to Incyte Corp.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for INCY in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for INCY.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.